NCT03829462View on ClinicalTrials.gov

Assessing a Regorafenib-irinotecan Combination Versus Regorafenib Alone in Metastatic Colorectal Cancer Patients

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

377

Participants

Timeline

Start Date

March 28, 2019

Primary Completion Date

September 4, 2024

Study Completion Date

September 30, 2025

Conditions
Metastatic Colorectal Cancer (mCRC)
Interventions
DRUG

Regorafenib

regorafenib tab 40 mg i.e 160 mg/day

DRUG

Irinotecan

irinotecan 120 mg/m2 cycle 1, 150 mg/m2 cycle 2, 180 mg/m2 cycle 3 and more

Trial Locations (11)

14000

Centre François Baclesse, Caen

34298

CRLC Val d'Aurelle-Paul Lamarque, Montpellier

35000

Hôpital Pontchaillou, Rennes

51100

Hôpital Robert Debré, Reims

Institut Godinot, Reims

66000

Hôpital Saint-Jean, Perpignan

69008

Centre Léon Bérard, Lyon

Hôpital privé Jean Mermoz, Lyon

75015

Hôpital Européen Georges Pompidou, Paris

94800

Institut Gustave Roussy, Villejuif

06189

Centre Antoine Lacassagne, Nice

All Listed Sponsors
lead

Institut du Cancer de Montpellier - Val d'Aurelle

OTHER